CDNA · XBRL financial data

CareDx financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CDNA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	192,194	296,397	321,793	280,324	333,785	379,805
Research and development	48,941	76,525	90,388	81,866	72,405	71,429
General and administrative	48,806	74,964	100,397	117,868	123,784	107,565
Total operating expenses	214,722	326,123	399,024	483,687	293,020	410,586
Operating income (loss)	(22,528)	(29,726)	(77,231)	(203,363)	40,765	(30,781)
Other income (expense)	(811)	(2,628)	(2,872)	1,343	329	524
Income tax expense (benefit)	(1,036)	(1,426)	379	141	310	271
Net income (loss)	(18,714)	(30,662)	(76,613)	(190,284)	52,549	(21,354)
Earnings per share, basic USD per share	(0.40)	(0.59)	(1.44)	(3.54)	1.00	(0.40)
Earnings per share, diluted USD per share	(0.40)	(0.59)	(1.44)	(3.54)	0.93	(0.40)
Weighted average shares, basic thousands of shares	46,482	52,241	53,322	53,765	52,773	53,288
Weighted average shares, diluted thousands of shares	46,482	52,241	53,322	53,765	56,621	53,288

Fiscal years (CDNA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	134,669	348,485	89,921	82,197	114,689	65,429
Marketable securities	90,034	0	203,168	153,221	145,964	111,779
Marketable securities, non-current	—	—	—	—	0	24,165
Accounts receivable	34,624	59,761	66,312	51,061	64,605	42,628
Inventory	10,012	17,186	19,232	19,471	19,503	26,705
Prepaid and other current assets	3,758	7,928	9,216	7,763	7,071	10,591
Total current assets	273,097	433,360	387,849	313,713	351,832	257,132
Property and equipment, net	10,704	22,044	35,529	35,246	33,552	32,971
Right-of-use asset	15,228	17,993	34,689	29,891	24,340	22,760
Goodwill	23,857	36,983	37,523	40,336	40,336	40,336
Total assets	368,511	566,621	542,991	466,826	491,050	413,228
Accounts payable	9,653	13,337	9,942	12,872	7,686	9,988
Current portion of long-term debt	0	—	—	—	—	—
Total current liabilities	69,217	77,301	75,975	78,072	89,371	89,849
Long-term debt	0	—	—	—	—	—
Lease liability, non-current	16,069	17,394	33,406	28,278	22,263	19,679
Total liabilities	90,832	100,745	112,080	205,498	112,617	110,127
Accumulated deficit	(352,527)	(383,189)	(460,444)	(678,269)	(626,242)	(735,359)
Total stockholders' equity	277,679	465,876	430,911	261,328	378,433	303,101
Total liabilities and equity	368,511	566,621	542,991	466,826	491,050	413,228
Common shares outstanding (cover page) thousands of shares	51,823	53,025	53,674	51,779	55,426	51,216

Fiscal years (CDNA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(18,714)	(30,662)	(76,613)	(190,284)	52,549	(21,354)
Stock-based compensation	23,401	36,081	46,553	49,086	66,406	34,864
Depreciation and amortization	—	8,797	11,595	14,386	14,194	15,018
Net cash from operating activities	33,431	(19,294)	(25,239)	(18,388)	38,048	42,032
Net cash from investing activities	(100,394)	47,712	(228,502)	40,446	(483)	2,158
Proceeds from issuing common stock	—	188,855	0	0	—	—
Share repurchases	0	0	642	27,541	522	87,768
Net cash from financing activities	163,149	185,642	(4,535)	(29,606)	(5,606)	(93,394)
Net change in cash	96,460	213,757	(258,253)	(7,660)	32,491	(49,294)

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
CareDx	250,480	139,362	12,718*	52.5M	—	Q3 FY26 10-QSep 30, 2026
BillionToOne	561,512	122,981	12,547*	not reported	—	Q3 FY26 10-QSep 30, 2026
Veracyte	299,521	150,321	45,826*	80.4M	—	Q2 FY26 10-QJun 30, 2026
Personalis	98,271	25,596	(27,072)*	108.4M	6.7 quarters	Q3 FY26 10-QSep 30, 2026
Castle Biosciences	62,116	103,546	15,201*	30.5M	—	Q2 FY26 10-QJun 30, 2026
Lumexa Imaging Holdings	69,705	264,162	32,801*	96.1M	—	Q2 FY26 10-QJun 30, 2026
GRAIL	55,645	44,687	(80,730)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Celcuity	182,049	not reported	(55,426)*	48.9M	13.6 quarters	Q2 FY26 10-QJun 30, 2026
Fortrea Holdings	220,600	691,500	60,800*	96.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.